The 37 Connectors

The public record binds the Mass General Brigham (MGB) institutional family and the Thermo Fisher Scientific (Thermo Fisher) corporate family across thirty-seven separately indexed connector records or relationship families. The connections travel through licenses, biological material, joint research, product-development input, disclosed purchasing, installed platforms, federal pass-through awards, clinical trials, sponsored research, royalties, commercialization services, sponsorship, and institutional promotion. The matrix divides that record into a corporate-umbrella registry and a connector ledger; together, the two tables preserve the legal entity, period, acquisition posture, evidence class, documented connector, proof limit, and source trail for every row.¹

This companion post carries the complete evidentiary ledger behind “Dogs of MGB”; it doesn’t convert thirty-seven rows into thirty-seven contracts, payments, conflicts, current relationships, or Board-approved matters.

The recurrence is the evidence; the restraint is part of the record.

What This Counts

The matrix admits a connector when a primary, official, institutional, or counterparty record places one entity from each family inside the same transaction, agreement, license, payment, product workflow, sponsored study, clinical-trial infrastructure, service arrangement, or institutional promotion. The matrix excludes routine methods-section mentions of generic reagents, consumables, or catalog items. A separate row requires an institutional record, a counterparty record, a named program or platform, a formal relationship, or another fact above routine laboratory use.

The evidence classes carry separate loads. The “A” class establishes a transaction, agreement, license, payment, selected product, or named collaborator. The “B” class establishes operational use, a shared program, or product-development input without necessarily establishing a contract. The “C” class establishes sponsorship, marketing, education, or portfolio adjacency as context rather than procurement proof. A slash joins two classes when one connector crosses the evidentiary boundary.

The count admits one underlying relationship family once; payment direction remains descriptive rather than controlling admission, while the acquisition gate marks every pre-acquisition connector as later acquired without making Thermo Fisher Scientific (Thermo Fisher) a historical party merely because Thermo Fisher later bought the company.

The Corporate Umbrellas

Corporate Lineage, Institutional Identity, and Acquisition Timing Across Twenty-Five Registry Entries

The registry traces the Thermo Fisher Scientific (Thermo Fisher) corporate family through seven postures: predecessors, subsidiaries, acquired businesses, product families, distribution channels, divested product history, and screened names. The same registry preserves seven identities across the Mass General Brigham (MGB) institutional family: a renamed system parent, member hospitals, legal corporate entities, research programs, clinical centers, operational units, and a venture arm. The table keeps every name, posture, and timing rule intact.²

---

Side	Entity or Brand	Umbrella Posture	Timing Rule
Thermo Fisher Scientific (Thermo Fisher)	Thermo Electron Corporation	Thermo Fisher predecessor	Thermo Electron merged with Fisher Scientific in November 2006.
Thermo Fisher	Thermo Cardiosystems Inc.	Historical Thermo Electron public subsidiary in the 2000 record	The registry doesn’t describe Thermo Cardiosystems Inc. as a current Thermo Fisher subsidiary.
Thermo Fisher	Fisher Scientific International Inc. and the Fisher Scientific channel	Thermo Fisher predecessor and current channel	The registry separates pre-2006 Fisher records from post-merger Fisher-channel records.
Thermo Fisher	Fisher BioServices	Current Thermo Fisher subsidiary named in Exhibit 21	The federal pass-through records preserve Fisher BioServices as the named entity.
Thermo Fisher	BRAHMS GmbH	Current Thermo Fisher subsidiary	Thermo Fisher acquired BRAHMS on October 1st, 2009.
Thermo Fisher	One Lambda	Current Thermo Fisher subsidiary	Thermo Fisher acquired One Lambda in September 2012.
Thermo Fisher	Life Technologies Corporation	Current Thermo Fisher subsidiary	Thermo Fisher acquired Life Technologies on February 3rd, 2014; earlier Invitrogen, Applied Biosystems, and Ion Torrent relationships remain legacy relationships.
Thermo Fisher	Invitrogen	Current Thermo Fisher brand and entity family through Life Technologies	The Massachusetts General Hospital (MGH) licenses and biological-material inputs documented in December 2002 predate Thermo Fisher ownership.
Thermo Fisher	Applied Biosystems, Ion Torrent, TaqPath, and Oncomine	Current Thermo Fisher product families, principally through Life Technologies	The registry doesn’t recast institutional use before February 2014 as Thermo Fisher-controlled at the time.
Thermo Fisher	Affymetrix and eBioscience	Current Thermo Fisher corporate family	Affymetrix acquired eBioscience in June 2012, and Thermo Fisher acquired Affymetrix on March 31st, 2016.
Thermo Fisher	FEI Company	Current Thermo Fisher corporate family	Thermo Fisher acquired FEI on September 19th, 2016.
Thermo Fisher	Patheon	Current Thermo Fisher pharmaceutical-services brand and entity family	Thermo Fisher acquired Patheon on August 29th, 2017.
Thermo Fisher	PPD and PPD Development	Current Thermo Fisher clinical-research-services family	Thermo Fisher acquired PPD on December 8th, 2021; earlier trials and pass-through awards remain legacy relationships.
Thermo Fisher	CorEvitas	Current Thermo Fisher and PPD real-world-evidence and clinical-registry business	Thermo Fisher acquired CorEvitas on August 14th, 2023, and MGH currently identifies an enrolling registry conducted with CorEvitas.
Thermo Fisher	The Binding Site	Current Thermo Fisher diagnostics business	Thermo Fisher acquired The Binding Site on January 3rd, 2023, while MGH instrument use began earlier.
Thermo Fisher	Olink	Current Thermo Fisher proteomics business	Thermo Fisher acquired Olink on July 10th, 2024; earlier MGH collaborations remain legacy relationships.
Thermo Fisher	Epredia and legacy Thermo Anatomical Pathology products	Former Thermo Fisher business rather than a current Thermo Fisher subsidiary	Thermo Fisher completed the sale to PHC Holdings Corporation in June 2019 and lists Arcos and ArcosSL among the divested products.
Thermo Fisher	Phadia, Dionex, Remel, Oxoid, Nalge Nunc, Unity Lab Services, Brammer Bio, and Clario	Current Thermo Fisher entities or brands screened during the targeted pass	The targeted pass established no direct public connector for these names after screening the institutional umbrella, while Unity remains a brand rather than the exact legal-entity name in the 2025 subsidiary exhibit.
Mass General Brigham (MGB)	Partners HealthCare System, Inc. (Partners) and Mass General Brigham Incorporated	System parent and predecessor or current-name chain	MGH and Brigham and Women’s Hospital (BWH) formed Partners in 1994; the system adopted the MGB name in 2019.
MGB	Massachusetts General Hospital and The General Hospital Corporation	MGB member and its legal corporate entity	The registry preserves the source-native name in every row.
MGB	BWH	MGB member	The matrix doesn’t relabel hospital receipts as MGB-parent receipts.
MGB	Brigham and Women’s Faulkner Hospital	MGB member	The matrix preserves separate Schedule L recipient rows.
MGB	MGB Biobank, Personalized Medicine, and system research cores	MGB programs and operational units	A product requirement establishes a workflow connector rather than a systemwide exclusive contract.
MGB	Mass General Brigham Ventures	MGB venture arm	A portfolio company remains MGB-linked rather than automatically becoming an MGB subsidiary or pension asset.
MGB	The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard	BWH and Harvard center	The matrix treats the center as a mixed institutional center rather than the MGB parent.

---

The registry carries twenty-five data rows: eighteen on the Thermo Fisher Scientific (Thermo Fisher) side and seven on the Mass General Brigham (MGB) side. Thermo Fisher anchors the corporate family through its current Form 10-K and subsidiary exhibit, while MGB’s member page and system history anchor the institutional family. The registry preserves related names without converting them into the same legal person; the row order keeps corporate branches together, sequences comparable acquisitions by date, and isolates former, divested, or screened names at the end of the Thermo Fisher block.

The Connector Ledger

Chronology, Evidence Classes, and Proof Limits Across Thirty-Seven Records

The ledger below carries every admitted connector and its matching proof limit. The “Number” column orders the records by the earliest relationship date that the public record supports; the “Class” column applies the “A”, “B”, and “C” distinctions from the admission rule. The final column states the conclusion that remains beyond each row’s proof.

---

Number	Period	Thermo Fisher Scientific (Thermo Fisher) Family Entity	Mass General Brigham (MGB) Family Entity	Class	Documented Connector	What the Record Does Not Establish
1	2000	Thermo Cardiosystems Inc., then a public Thermo Electron subsidiary	Brigham and Women’s Hospital (BWH)	B	A Thermo Cardiosystems Inc. release listed BWH among approved Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) centers evaluating the HeartMate left ventricular assist system (LVAS).3	That BWH purchased the device, paid Thermo Cardiosystems Inc., selected the company outside the trial protocol, or dealt with the present Thermo Fisher parent.
2	October 2002	Thermo Electron	Partners HealthCare (Partners)	A	Thermo Electron and Partners launched a formal proteomics collaboration: Thermo Electron donated four systems and placed a scientist in residence, and Partners researchers supplied access, evaluation, and product feedback.4	A cash payment, exclusivity, intellectual-property ownership, director participation, or a present agreement.
3	By December 2002	Invitrogen, independent at the time	Massachusetts General Hospital (MGH) Cancer Center	A	Invitrogen’s ProQuest manual says MGH Cancer Center researchers supplied C. elegans ribonucleic acid (RNA) used to generate a commercial pre-made complementary DNA (cDNA) library.5	Ownership terms, consideration, a hospital-level agreement, or Thermo Fisher involvement at the time.
4	By December 2002	Invitrogen, independent at the time	MGH and Johns Hopkins University	A	The same ProQuest manual says one or both of U.S. Patents 5,955,280 and 5,965,368 were licensed to Invitrogen by MGH and Johns Hopkins University for the Reverse Two-Hybrid product family.6	The royalty rate, allocation between licensors, duration, later revenue, or Thermo Fisher involvement at the time.
5	Fiscal year 2002 filing	Thermo Electron filing and MGH program	MGH	C	Thermo Electron filed MGH’s Executive Registry and Corporate Care program description as a Form 10-K exhibit, documenting a corporate-health-benefit channel inside Thermo Electron’s filing record.7	The subscribing Thermo Electron entity, price, term, eligible executives, or use by any named executive.
6	October 2004; relationship ended by July 2007	Thermo Electron	MGH	A	Thermo Electron and MGH opened the Biomarker Research Initiatives in Mass Spectrometry (BRIMS) as a joint research center: MGH supplied scientific and clinical expertise, while Thermo Electron supplied personnel, instruments, software, services, and the Cambridge facility. A July 2007 account says the MGH relationship had ended.8	Continuous operation after 2007, undisclosed intellectual-property or revenue allocation, or improper influence.
7	Fiscal years 2008 and 2009	ThermoFisher	BWH	A	BWH’s fiscal year 2008 return disclosed ThermoFisher products and services, and its fiscal year 2009 return disclosed an $11,235,649 products transaction.9	Product detail, competitive process, current spending, personal benefit, or a safe ThermoFisher amount for the malformed fiscal year 2008 sentence.
8	2009 purchase; Thermo Fisher ownership from 2016	FEI	MGH	A	MGH’s diagnostic electron-microscopy service says it purchased an FEI Morgagni transmission electron microscope in 2009.10	Thermo Fisher control at purchase, price, maintenance terms, or continued current use.
9	2011	Thermo Fisher	MGH researchers	B	Thermo Fisher reported that MGH researchers used LTQ Orbitrap Velos and TSQ Vantage systems in stroke-biomarker work.11	Central procurement, equipment ownership, purchase price, or a new collaboration agreement.
10	2011; Thermo Fisher ownership from 2014	Ion Torrent and Life Technologies	MGH Pathology	B	MGH’s pathology history describes developmental initiatives with Ion Torrent for broad cancer genotyping.12	Thermo Fisher control at the time, exclusive use, payment, or present contract terms.
11	Fiscal years 2012 through 2014	ThermoFisher	Partners parent, BWH, and Brigham and Women’s Faulkner Hospital (BWFH)	A	Partners HealthCare (Partners) returns for three fiscal years report ThermoFisher products transactions of $15,164,678, $17,010,411, and $24,219,046, and separate affiliates-group returns report recurring BWH and BWFH transactions in the same years.13	A lawful cumulative parent-plus-group total, because centralized procurement and intercompany allocation may overlap; duplicate interested-person rows aren’t extra purchases.
12	Fiscal year 2012; Thermo Fisher ownership from 2016	eBioscience and Affymetrix	MGH	A	Partners’ federal single audit lists $218 from MGH to “eBioscience Affymetrix” in its subrecipient table.14	Materiality, Thermo Fisher control at the time, the underlying scientific work, or a commercial purchase.
13	Fiscal years 2013 and 2014	Fisher BioServices	MGH	A	Partners single audits list Fisher BioServices as federal pass-through sponsor to MGH under HHSN272201200022C, with $71,386 in fiscal year 2013 and $14,636 in fiscal year 2014, and the National Institutes of Health (NIH) identifies that contract as the National Institute of Allergy and Infectious Diseases (NIAID) AIDS Reagent Program.15	A purchase by MGH, discretionary hospital selection of Fisher BioServices, or involvement by MGB’s Board of Directors.
14	Study windows from 2013 through 2029; Thermo Fisher ownership from December 2021	PPD Development	MGH and BWH	B	ClinicalTrials.gov places PPD Development with MGH or BWH across six sponsor or collaborator records.16	Hospital selection or payment of PPD, Thermo Fisher ownership throughout every study, or one bilateral contract behind every shared listing.
15	Pre-2014 legacy license	Invitrogen, independent at the time	MGH	A	An Invitrogen Interaction Trap manual says U.S. Patent 5,580,736 was owned by MGH and licensed to Invitrogen for research.17	Consideration, present enforceability, current royalties, or identity with the ProQuest patent family.
16	Purchase predating the 2014 suit; record published in 2016	Fisher Scientific	Partners and The General Hospital Corporation	A	A federal report says the plaintiffs alleged purchasing a scientific freezer from Fisher before compressor failure and sample loss, and Fisher settled and was dismissed.18	Purchase date, price, Fisher liability, negligence, Board participation, or settlement terms.
17	Fiscal years 2014, 2015, and 2017; Thermo Fisher ownership from 2021	PPD Development	BWH and the Partners system	A	Partners single audits list PPD Development as a federal pass-through sponsor under NIH contract numbers, with BWH or system expenditures in three audited years.19	Thermo Fisher control at the time, commercial procurement by BWH, complete program terms, or present payments.
18	2014	BRAHMS, already Thermo Fisher-owned	BWH	B	A BWH pathology manual identifies two Thermo BRAHMS KRYPTOR analyzers in its clinical laboratory.20	Purchase price, ownership versus reagent placement, maintenance terms, or systemwide use.
19	Observations from 2014 through 2021; Thermo Fisher ownership from 2023	The Binding Site	MGH	B	An MGH laboratory study says serum free-light-chain testing used a Binding Site Optilite turbidimeter and describes MGH ordering and alert workflows.21	Thermo Fisher control during the study period, procurement terms, exclusivity, or a current systemwide arrangement.
20	2015; Thermo Fisher ownership from 2016	Affymetrix	MGH and scientists affiliated with the Broad Institute of MIT and Harvard	B	An Affymetrix Axiom Transplant Genotyping Array document names MGH and Broad Institute scientists in its design group.22	An MGH institutional contract, compensation, exclusive rights, or Thermo Fisher involvement at the time.
21	From 2015	Thermo Fisher Oncomine and Ion Torrent	MGH	B	The National Cancer Institute and MGH records place MGH in the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) standardized workflow and identify Thermo Fisher’s Oncomine assay in the program lineage; current MGH materials continue to feature Ion Torrent and Oncomine workflows.23	Independent selection or payment by MGH, a bilateral contract, or one uninterrupted assay version.
22	From 2020; Thermo Fisher ownership from July 2024	Olink	MGH	A/B	Olink records document a COVID-19 collaboration with MGH, plasma-based immuno-oncology work by an MGH melanoma surgeon, and an inflammatory-protein comparison conducted with MGH.24	One continuous agreement, MGB-parent contracting, historical Thermo Fisher control, or payment terms.
23	2020	Thermo Fisher and Applied Biosystems	BWH	B	A peer-reviewed BWH laboratory-operations article identifies Thermo Fisher’s TaqPath COVID-19 assay and the Applied Biosystems 7500 Fast Dx platform in the hospital workflow.25	Procurement terms, revenue, exclusivity, or approval by an MGB-family Board of Directors.
24	2020 award	Thermo Fisher	BWH postdoctoral researcher	C	Thermo Fisher’s Tandem Mass Tag (TMT) Research Grant Award announcement records a silver-level award to BWH postdoctoral fellow Samuel Whedon.26	A hospital contract, institutional endorsement, or material financial dependence.
25	2020, 2021, 2022, and 2024	Thermo Fisher and Marc Casper, then Chairman of the Board of Directors, President, and Chief Executive Officer (CEO)	World Medical Innovation Forum, hosted by MGB	C	World Medical Innovation Forum records place Casper in four editions: a 2020 fireside moderated by MGB’s Chief Financial Officer (CFO), a 2021 gene-and-cell-therapy partnering fireside, and featured firesides or speaker roles in 2022 and 2024.27	A Thermo Fisher sponsorship, speaking fee, commercial agreement, procurement role, or influence over MGB science or investment decisions.
26	Payments from 2021 through 2023; publication through 2026	BRAHMS and Thermo Fisher	MGH lead; Martha’s Vineyard Hospital and North Shore Medical Center trial locations	A	The Centers for Medicare & Medicaid Services (CMS) records show $1,050,200 in BRAHMS research payments to MGH across six disclosures, and ClinicalTrials.gov names MGH as lead sponsor, BRAHMS and Thermo Fisher as collaborators, and two additional MGB-family hospital locations.28	Payments to the additional sites, new payments after 2023, product approval, MGB-parent revenue, or misconduct.
27	Publicly documented in November and December 2021; Thermo Fisher divestiture in June 2019	Fisher Healthcare, a current Thermo Fisher channel, and Epredia Arcos, a divested former-Thermo Fisher product line	MGH Histopathology	A	Fisher Healthcare says MGH implemented the Epredia Arcos Tissue Block Management System, and a contemporaneous Fisher-sponsored account describes the demonstration and quotes MGH’s laboratory leader calling the hospital an early adopter.29	Purchase agreement, price, implementation date, competitive process, present use, or Thermo Fisher ownership of Epredia when the 2021 materials appeared.
28	2023 through 2025	Life Technologies Corporation	BWH and MGH	A	CMS classifies Life Technologies payments totaling $350,778.21 to BWH and a separate $9,256.30 payment to MGH as “Royalty or License”.30	The covered patents, payment formula, relationship to ExoTRU, MGB-parent receipt, or spending from MGB to Thermo Fisher.
29	January 2025	Thermo Fisher clinical-research and Patheon manufacturing services	Lyndra Therapeutics, a company linked to Mass General Brigham Ventures (MGBV)	C/A	MGBV carried Lyndra’s announcement, and Lyndra says Thermo Fisher will provide global clinical-research and commercial-manufacturing services, including a Phase 3 safety study and Cincinnati manufacturing.31	Lyndra as an MGB subsidiary, MGB ERISA Master Trust ownership, MGB selection of Thermo Fisher, or MGB receipt of the contract payments.
30	2025	One Lambda and Thermo Fisher, with Bio-Techne Corporation and its Exosome Diagnostics brand as intermediaries	BWH Azzi Lab and MGB Innovation lineage	A	MGB says Brigham-origin ExoTRU was licensed to Thermo Fisher, Bio-Techne Corporation describes development with the Azzi Lab and an exclusive Thermo Fisher development-and-commercialization arrangement, and One Lambda now offers the laboratory service.32	Direct BWH-to-Thermo Fisher contracting without the executed chain, consideration, royalties, Food and Drug Administration (FDA) clearance, or approval by an MGB-family Board of Directors.
31	2025	Thermo Fisher corporate team or sponsor	BWH fundraising event	C	BWH’s Boston 10K sponsor page lists a “Thermo-Fisher” team or sponsor.33	Procurement, influence, material financial value, or MGB-parent sponsorship.
32	Late 2025	Fisher Scientific channel	MGB	A	Fisher’s MGB contract flyer says the channel is now MGB’s preferred research-products provider, with MGB Marketplace ordering, price locks, savings programs, delivery benefits, and named Fisher and MGB contacts.34	Actual spending, purchase count, term, exclusivity, legal counterparty, bid record, rebates, product mix, conflicts, or approvals.
33	Current page checked in 2026	PPD, part of Thermo Fisher	The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center)	C	The MRCT Center lists PPD as a Steering Committee sponsor and says sponsor participants review and rank prospective projects.35	A unique PPD privilege, MGB-parent sponsorship, access to confidential intellectual property, procurement, or Board Investment Committee jurisdiction.
34	Current pages checked in 2026	Applied Biosystems, Life Technologies, and Thermo Fisher	MGB Biobank, MGH Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, Partners Peptide and Protein Core, and BWH NeuroTechnology Studio	B	MGB and member-core pages name TaqMan availability through Thermo Fisher, Applied Biosystems 7000 and 7500 instruments, Life Technologies and Applied Biosystems peptide equipment, and a QuantStudio 6 Pro installed in 2023.36	One centralized contract, continuous maintenance, an exclusive supply agreement, or exact spending.
35	Current page checked in 2026	Thermo Scientific	MGH Cancer Center	B	The Haas Lab says it acquired an Orbitrap Astral through an NIH Shared Instrumentation Grant.37	Hospital unrestricted-fund spending, price, vendor-selection process, or systemwide adoption.
36	Current or recent public pages	Thermo Fisher and Fisher content platforms	MGH clinicians and laboratories	C	Fisher Healthcare features MGH cardiologist James Januzzi in a biomarker webinar, Thermo Fisher Oncomine pages feature MGH physicians Lauren Ritterhouse, Ibiayi Dagogo-Jack, Amir Fathi, and Valentina Nardi, and Thermo Fisher’s Binding Site page uses an MGH laboratory-testing case study.38	A common payment arrangement, hospital endorsement, institutional contracting, or employment by MGB for the content.
37	Current page checked in 2026; Thermo Fisher ownership from August 2023	CorEvitas, now within Thermo Fisher and PPD	MGH Neuroimmunology Clinic	B	MGH says its Synergy of Prospective Health and Experimental Research for Emerging Solutions in Neuromyelitis Optica Spectrum Disorder (SPHERES) registry is conducted with the Guthy-Jackson Charitable Foundation and CorEvitas and is currently enrolling.39	The registry agreement, funding, data rights, MGB-parent contracting, exclusivity, director involvement, or MGH’s pre-acquisition participation.

---

The rows are data points, not interchangeable units. The count establishes recurrence across more than twenty-five years without creating a cumulative money flow. The count establishes neither thirty-seven contracts nor thirty-seven matters handled by the same governance body.

Four Directions Converge

The first direction carries science from the Mass General Brigham (MGB) institutional family into products and services from the Thermo Fisher Scientific (Thermo Fisher) corporate family through ProQuest licensing, Interaction Trap licensing, Massachusetts General Hospital (MGH) biological material, Biomarker Research Initiatives in Mass Spectrometry (BRIMS) feedback, Olink collaborations, Axiom design input, and ExoTRU commercialization.

The second direction carries products and services from the Thermo Fisher Scientific (Thermo Fisher) corporate family into operations across the Mass General Brigham (MGB) institutional family through disclosed purchasing, installed platforms, selected products, research-core equipment, clinical workflows, distribution channels, and the preferred-provider agreement.

The third direction joins the Mass General Brigham (MGB) institutional family and the Thermo Fisher Scientific (Thermo Fisher) corporate family inside federal and clinical-research infrastructure through Fisher BioServices, PPD pass-through awards and linked trials, the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH), ProSAVE, and sponsorship of the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center).

The fourth direction returns value, access, or visibility from the Mass General Brigham (MGB) institutional family toward the Thermo Fisher Scientific (Thermo Fisher) corporate family through Life Technologies royalties, ExoTRU, Lyndra’s service arrangement, research awards, forum appearances, sponsorships, and clinician-facing content.

The four directions classify movement rather than isolate rows. A single connector can cross more than one direction when the record carries science, products, money, access, or visibility through the same route. The complete pattern converges into recurrence without collapsing into one contract, one payment stream, one commercial loop, one governance route, or one decision-maker.

Names Stay Separate

The seven distinctions below prevent the umbrella method from laundering a related entity into a contracting party.

• Bio-Techne Corporation occupied the corporate middle of the ExoTRU route through its Exosome Diagnostics brand; the record converts neither name into Thermo Fisher Scientific or Mass General Brigham.
• Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, Harvard University, and Johns Hopkins University remain collaborators or co-licensors rather than subsidiaries of Mass General Brigham.
• Epredia has belonged to PHC Holdings Corporation since the June 2019 divestiture; its Arcos lineage carries former ownership by Thermo Fisher Scientific, while Fisher Healthcare supplies the current channel within that corporate family.
• Gulf Scientific Corporation appears only in the screened research trail as an independent regional partner or distributor of Thermo Fisher Scientific; Gulf Scientific enters neither the corporate umbrella registry nor the thirty-seven-connector count.
• Lyndra Therapeutics remains linked to Mass General Brigham Ventures rather than becoming a subsidiary of Mass General Brigham (MGB) or an asset of the MGB ERISA Master Trust.
• The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard remains a joint center rather than the Mass General Brigham parent.
• Thermo Fisher Scientific can bring a relationship into today’s corporate umbrella through a later acquisition without becoming the historical selecting, negotiating, or governing party.

The row survives only when its names survive.

The Governance Gate

Mass General Brigham (MGB) routes ordinary goods-and-services contracts through Mass General Brigham Supply Chain, funded clinical-research agreements from for-profit entities through the Clinical Trials Office (CTO), funded nonclinical research agreements from for-profit entities and invention-commercialization services through Mass General Brigham Innovation, and designated industry-interaction matters through the Office for Interaction with Industry (OII). The routing record assigns separate institutional lanes to Supply Chain, the CTO, MGB Innovation, and the OII; it supplies no connector-specific assignment to the Board Investment Committee (BIC). Within MGB, the public record leaves the BIC as a governance question rather than a documented connector route.⁴⁰

Within Mass General Brigham (MGB), the Board of Directors bears responsibility for selecting professional managers that assist the MGB ERISA Master Trust. MGB’s audited financial statements separately assign pension oversight and external-manager selection to the Board Investment Committee (BIC). Those duties connect this matrix to “Dogs of MGB” through Board authority and public-record opacity surrounding the BIC rather than an invented claim that the BIC handled laboratory procurement, licenses, research agreements, or clinical platforms.⁴¹

Mass General Brigham (MGB) should identify any office or governance body that approved, reviewed, priced, routed, monitored, licensed, or accepted each connector within MGB’s control, state when no review occurred, and publish every surviving conflict, recusal, fairness, approval, and no-review record.

The Source Record

A public footnote attaches to the claim location it documents; the note combines sources only when those sources jointly support that claim. The source ledger preserves a request for the following records; the reviewed public trail hasn’t supplied the requested records. The list frames a disclosure request rather than a finding about conduct.⁴²⁴²

• The requested acquired-company records include Board rosters for Affymetrix, Inc., Applied Biosystems Inc., B.R.A.H.M.S. AG, FEI Company, Invitrogen Corporation, Life Technologies Corporation, Olink Holding AB (publ), One Lambda, Inc., Patheon N.V., PPD, Inc., and The Binding Site Group.
• Biomarker Research Initiatives in Mass Spectrometry, ExoTRU, the Fisher Scientific preferred-provider agreement, Life Technologies Corporation licenses, Patheon service agreements, service agreements involving PPD, Inc., and ProSAVE agreements and amendments.
• Board Investment Committee records for Mass General Brigham (MGB), including the current charter, membership, delegations, minutes, external-manager selection records, external-manager fee records, conflict records, recusal records, and any direct or indirect Thermo Fisher Scientific exposure inside the MGB ERISA Master Trust.
• The competitive-selection record set includes files, category awards, group-purchasing or distributor agreements, value-analysis records, vendor scorecards, price benchmarks, and product-mix data.
• The conflict record set includes questionnaires, disclosure records, related-party reviews, recusals, independent-fairness findings, approval memoranda, and minutes that identify the actual governance body.
• The intellectual-property record set includes ownership, consideration, royalty formulas, revenue sharing, termination rights, commercialization milestones, and value allocation.
• The vendor record set includes vendor-master records, purchase orders, invoices, rebates, credits, warranties, maintenance agreements, leases, software, cloud, data-hosting, validation, and service records.

The matrix can grow only when a new public record clears the same admission rule, and its limits remain part of its evidence until that record arrives.

---

Source Notes

1. Thermo Fisher Scientific Inc. (Thermo Fisher), 2025 Form 10-K and Exhibit 21 Subsidiary List; Mass General Brigham (MGB), Members and Affiliations and System History. ↩︎
2. Thermo Fisher Scientific Inc. (Thermo Fisher), 2025 Form 10-K and Exhibit 21 Subsidiary List; Mass General Brigham (MGB), Members and Affiliations and System History. Thermo Fisher acquisition records for Affymetrix, Inc., FEI Company, PPD, Inc., The Binding Site Group, CorEvitas, and Olink Holding AB (publ). ↩︎
3. Thermo Cardiosystems Inc., “Thermo Cardiosystems Provides Update on Enrollment in REMATCH Trial”, August 31st, 2000. ↩︎
4. Thermo Electron Corporation, 2002 Partners HealthCare Collaboration Announcement, Massachusetts General Hospital (MGH) Executive Registry Exhibit, and 2004 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Announcement; Celia Henry Arnaud, “Inside Instrumentation”, Chemical & Engineering News, July 9th, 2007. ↩︎
5. Invitrogen, ProQuest Pre-made cDNA Libraries Instruction Manual and Interaction Trap System Manual. ↩︎
6. Invitrogen, ProQuest Pre-made cDNA Libraries Instruction Manual and Interaction Trap System Manual. ↩︎
7. Thermo Electron Corporation, 2002 Partners HealthCare Collaboration Announcement, Massachusetts General Hospital (MGH) Executive Registry Exhibit, and 2004 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Announcement; Celia Henry Arnaud, “Inside Instrumentation”, Chemical & Engineering News, July 9th, 2007. ↩︎
8. Thermo Electron Corporation, 2002 Partners HealthCare Collaboration Announcement, Massachusetts General Hospital (MGH) Executive Registry Exhibit, and 2004 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Announcement; Celia Henry Arnaud, “Inside Instrumentation”, Chemical & Engineering News, July 9th, 2007. ↩︎
9. Brigham and Women’s Hospital (BWH), fiscal year 2008 (FY2008) Form 990 and fiscal year 2009 (FY2009) Form 990; Partners HealthCare System, Inc. (Partners), parent Forms 990 for fiscal year 2012 (FY2012), fiscal year 2013 (FY2013), and fiscal year 2014 (FY2014); Partners affiliates group, FY2014 Form 990. ↩︎
10. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. Thermo Fisher Scientific (Thermo Fisher) acquisition records for Affymetrix, FEI, PPD, The Binding Site, CorEvitas, and Olink. ↩︎
11. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. ↩︎
12. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. Thermo Fisher Scientific (Thermo Fisher) acquisition records for Affymetrix, FEI, PPD, The Binding Site, CorEvitas, and Olink. ↩︎
13. Brigham and Women’s Hospital (BWH), fiscal year 2008 (FY2008) Form 990 and fiscal year 2009 (FY2009) Form 990; Partners HealthCare System, Inc. (Partners), parent Forms 990 for fiscal year 2012 (FY2012), fiscal year 2013 (FY2013), and fiscal year 2014 (FY2014); Partners affiliates group, FY2014 Form 990. ↩︎
14. Partners HealthCare System (Partners), federal single audits for fiscal year 2012 (FY2012), fiscal year 2013 (FY2013), fiscal year 2014 (FY2014), fiscal year 2015 (FY2015), and fiscal year 2017 (FY2017); National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) AIDS Reagent Program notice. Thermo Fisher Scientific (Thermo Fisher) acquisition records for Affymetrix, FEI, PPD, The Binding Site, CorEvitas, and Olink. ↩︎
15. Partners HealthCare System (Partners), federal single audits for fiscal year 2012 (FY2012), fiscal year 2013 (FY2013), fiscal year 2014 (FY2014), fiscal year 2015 (FY2015), and fiscal year 2017 (FY2017); National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) AIDS Reagent Program notice. ↩︎
16. ClinicalTrials.gov, NCT01919801, NCT02533180, NCT03644667, NCT04998851, NCT06052059, and NCT07015996; Thermo Fisher Scientific (Thermo Fisher), “Thermo Fisher Scientific Completes Acquisition of PPD”, December 8th, 2021. ↩︎
17. Invitrogen, ProQuest Pre-made cDNA Libraries Instruction Manual and Interaction Trap System Manual. ↩︎
18. U.S. District Court for the District of Massachusetts, report and recommendation and memorandum in Partners HealthCare System, Inc. et al. v. Fisher Scientific Company LLC et al., May 16th, 2016 and August 22nd, 2016. ↩︎
19. Partners HealthCare System (Partners), federal single audits for fiscal year 2012 (FY2012), fiscal year 2013 (FY2013), fiscal year 2014 (FY2014), fiscal year 2015 (FY2015), and fiscal year 2017 (FY2017); National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) AIDS Reagent Program notice. ClinicalTrials.gov, NCT01919801, NCT02533180, NCT03644667, NCT04998851, NCT06052059, and NCT07015996; Thermo Fisher Scientific (Thermo Fisher), “Thermo Fisher Scientific Completes Acquisition of PPD”, December 8th, 2021. ↩︎
20. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. ↩︎
21. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. Thermo Fisher Scientific (Thermo Fisher) acquisition records for Affymetrix, FEI, PPD, The Binding Site, CorEvitas, and Olink. ↩︎
22. Olink, Massachusetts General Hospital (MGH) Melanoma Webinar, MGH COVID-19 Study, and MGH Inflammatory-Protein White Paper; Thermo Fisher Scientific (Thermo Fisher), Axiom Transplant Genotyping Array Content Summary; National Cancer Institute, National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) and National Clinical Laboratory Network Genomics Assays; Frederick National Laboratory, 2020 Annual Report. Thermo Fisher Scientific (Thermo Fisher) acquisition records for Affymetrix, FEI, PPD, The Binding Site, CorEvitas, and Olink. ↩︎
23. Olink, Massachusetts General Hospital (MGH) Melanoma Webinar, MGH COVID-19 Study, and MGH Inflammatory-Protein White Paper; Thermo Fisher Scientific (Thermo Fisher), Axiom Transplant Genotyping Array Content Summary; National Cancer Institute, National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) and National Clinical Laboratory Network Genomics Assays; Frederick National Laboratory, 2020 Annual Report. ↩︎
24. Olink, Massachusetts General Hospital (MGH) Melanoma Webinar, MGH COVID-19 Study, and MGH Inflammatory-Protein White Paper; Thermo Fisher Scientific (Thermo Fisher), Axiom Transplant Genotyping Array Content Summary; National Cancer Institute, National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) and National Clinical Laboratory Network Genomics Assays; Frederick National Laboratory, 2020 Annual Report. Thermo Fisher Scientific (Thermo Fisher) acquisition records for Affymetrix, FEI, PPD, The Binding Site, CorEvitas, and Olink. ↩︎
25. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. ↩︎
26. Thermo Fisher Scientific (Thermo Fisher), “Thermo Fisher Scientific Recognizes Tandem Mass Tag Grant Award Winners”, May 26th, 2020; ClinicalTrials.gov, ProSAVE; Centers for Medicare & Medicaid Services (CMS) Open Payments, BRAHMS research-payment records for 2021, 2022, and 2023. ↩︎
27. Brigham and Women’s Hospital (BWH), Archived 2025 Boston 10K Sponsor Page; Whitehat Communications, Fisher Healthcare Webinar Archive; Thermo Fisher Scientific (Thermo Fisher), “Molecular Testing for NSCLC with Rapid Tissue-Based NGS”, “Rapid NGS When Your Patients Need Answers”, and “Multiple Myeloma Clinical Testing Panels”; Mass General Brigham (MGB) medical forum records for 2020, 2021, and 2022; MGB, 2022 Forum Announcement and 2024 Forum Program. ↩︎
28. Thermo Fisher Scientific (Thermo Fisher), “Thermo Fisher Scientific Recognizes Tandem Mass Tag Grant Award Winners”, May 26th, 2020; ClinicalTrials.gov, ProSAVE; Centers for Medicare & Medicaid Services (CMS) Open Payments, BRAHMS research-payment records for 2021, 2022, and 2023. ↩︎
29. Fisher Scientific, Mass General Brigham (MGB) Contract Highlights and Massachusetts General Hospital (MGH) Patient Sample Management Webinar; The Journal of Healthcare Contracting, “Chain of Custody”. Thermo Fisher Scientific (Thermo Fisher), Anatomical Pathology Divestiture Notice; PHC Holdings Corporation, Epredia Acquisition Completion. ↩︎
30. Centers for Medicare & Medicaid Services (CMS) Open Payments, Life Technologies Corporation royalty-or-license records for 2023, 2024 Brigham and Women’s Hospital (BWH), 2024 Massachusetts General Hospital (MGH), and 2025; Mass General Brigham (MGB), ExoTRU Announcement; Bio-Techne Corporation, ExoTRU Development-and-License Announcement; Thermo Fisher Scientific (Thermo Fisher), One Lambda Exosomes Kidney Transplant Assay. ↩︎
31. Mass General Brigham Ventures (MGBV), Portfolio Company News; Lyndra Therapeutics, Thermo Fisher Scientific (Thermo Fisher) Services Announcement, January 14th, 2025. ↩︎
32. Centers for Medicare & Medicaid Services (CMS) Open Payments, Life Technologies Corporation royalty-or-license records for 2023, 2024 Brigham and Women’s Hospital (BWH), 2024 Massachusetts General Hospital (MGH), and 2025; Mass General Brigham (MGB), ExoTRU Announcement; Bio-Techne Corporation, ExoTRU Development-and-License Announcement; Thermo Fisher Scientific (Thermo Fisher), One Lambda Exosomes Kidney Transplant Assay. ↩︎
33. Brigham and Women’s Hospital (BWH), Archived 2025 Boston 10K Sponsor Page; Whitehat Communications, Fisher Healthcare Webinar Archive; Thermo Fisher Scientific (Thermo Fisher), “Molecular Testing for NSCLC with Rapid Tissue-Based NGS”, “Rapid NGS When Your Patients Need Answers”, and “Multiple Myeloma Clinical Testing Panels”; Mass General Brigham (MGB) medical forum records for 2020, 2021, and 2022; MGB, 2022 Forum Announcement and 2024 Forum Program. ↩︎
34. Fisher Scientific, Mass General Brigham (MGB) Contract Highlights and Massachusetts General Hospital (MGH) Patient Sample Management Webinar; The Journal of Healthcare Contracting, “Chain of Custody”. ↩︎
35. Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center), Our Sponsors. ↩︎
36. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. ↩︎
37. Massachusetts General Hospital (MGH), Diagnostic Electron Microscopy, Pathology History, Quantitative Real-Time Polymerase Chain Reaction (PCR) Core, and Haas Lab; Thermo Fisher Scientific (Thermo Fisher), 2011 Pittcon MGH Instrument Report; Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; American Journal of Clinical Pathology, MGH Binding Site Study; Mass General Brigham (MGB), Biobank Genomics Core; Partners HealthCare (Partners), Peptide and Protein Core; BWH, NeuroTechnology Studio; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow. ↩︎
38. Brigham and Women’s Hospital (BWH), Archived 2025 Boston 10K Sponsor Page; Whitehat Communications, Fisher Healthcare Webinar Archive; Thermo Fisher Scientific (Thermo Fisher), “Molecular Testing for NSCLC with Rapid Tissue-Based NGS”, “Rapid NGS When Your Patients Need Answers”, and “Multiple Myeloma Clinical Testing Panels”; Mass General Brigham (MGB) medical forum records for 2020, 2021, and 2022; MGB, 2022 Forum Announcement and 2024 Forum Program. ↩︎
39. Massachusetts General Hospital (MGH), Neuroimmunology Clinic; Thermo Fisher Scientific (Thermo Fisher), “Thermo Fisher Scientific Completes Acquisition of CorEvitas”, August 14th, 2023. ↩︎
40. Mass General Brigham (MGB), Supplier and Vendor Information, Working With Research Support Services, and Commercialization Guide for Innovators; MGB, Cash Balance Program Summary Plan Description and Fiscal Years 2025 and 2024 Audited Financial Statements. The routing page uses “Office for Interaction with Industry”, while the commercialization guide uses “Office for Interactions with Industry”; the body preserves the routing page’s source-native singular form. ↩︎
41. Mass General Brigham (MGB), Supplier and Vendor Information and Working With Research Support Services; MGB, Cash Balance Program Summary Plan Description and Fiscal Years 2025 and 2024 Audited Financial Statements. ↩︎
42. Partners HealthCare System (Partners) and Mass General Brigham (MGB) federal single-audit PDFs for fiscal years 2010 through 2025; the exact-name screen located positive rows in fiscal years 2012, 2013, 2014, 2015, and 2017 and establishes no absence outside those exact names. ↩︎